This company has been marked as potentially delisted and may not be actively trading. NYSE:ARA American Renal Associates (ARA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About American Renal Associates Stock (NYSE:ARA) 30 days 90 days 365 days Advanced Chart Get ARA alerts:Sign Up Key Stats Today's Range$11.33▼$11.5250-Day Range$11.46▼$11.5252-Week Range$5.57▼$11.98Volume9,831 shsAverage Volume106,940 shsMarket Capitalization$397.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts. Read More Receive ARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter. Email Address ARA Stock News HeadlinesBayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of CardiologyAugust 31, 2023 | benzinga.comAnemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateFebruary 22, 2023 | finance.yahoo.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...August 5 at 2:00 AM | InvestorPlace (Ad)Liberation From Renal Replacement Therapy and Early Initiation to Be Supported by The Kidney Function Biomarker Proenkephalin A 119-159 (penKid)January 11, 2023 | finance.yahoo.comContinuous Renal Replacement Therapy Global Market Report 2022: Rising Prevalence of Acute Kidney Injuries Drives DemandJanuary 1, 2023 | finance.yahoo.comDalian Atkinson: Footballer killed hours before renal treatmentOctober 7, 2022 | bbc.comBARA Appoints James Myers Vice President, Program Innovation and GrowthJune 22, 2022 | finance.yahoo.comAmerican Renal Associates Holdings, Inc. NewsJune 19, 2022 | thestreet.comSee More Headlines ARA Stock Analysis - Frequently Asked Questions How were American Renal Associates' earnings last quarter? American Renal Associates Holdings, Inc. (NYSE:ARA) posted its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.09. The business had revenue of $209.69 million for the quarter, compared to the consensus estimate of $211.50 million. American Renal Associates had a negative net margin of 2.04% and a negative trailing twelve-month return on equity of 3.56%. When did American Renal Associates IPO? American Renal Associates (ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers. What other stocks do shareholders of American Renal Associates own? Based on aggregate information from My MarketBeat watchlists, some other companies that American Renal Associates investors own include Zevra Therapeutics (KMPH), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Gilead Sciences (GILD), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings11/11/2020Today8/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNYSE:ARA CIK1498068 Webwww.americanrenal.com Phone978-922-3080FaxN/AEmployees4,977Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.26 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.79 million Net Margins-2.04% Pretax MarginN/A Return on Equity-3.56% Return on Assets-0.24% Debt Debt-to-Equity Ratio7.54 Current Ratio1.05 Quick Ratio1.02 Sales & Book Value Annual Sales$822.52 million Price / Sales0.48 Cash Flow$1.69 per share Price / Cash Flow6.80 Book Value$2.59 per share Price / Book4.45Miscellaneous Outstanding Shares34,543,000Free FloatN/AMarket Cap$397.94 million OptionableOptionable Beta1.11 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NYSE:ARA) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding American Renal Associates Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share American Renal Associates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.